Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice
Danai Dima, Fauzia Ullah, Sandra Mazzoni, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 2160-2160
Open Access | Times Cited: 18

Showing 18 citing articles:

Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management
Mariam Markouli, Fauzia Ullah, Serhan Ünlü, et al.
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6330-6352
Open Access | Times Cited: 21
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy
Danai Dima, Al‐Ola Abdallah, James A. Davis, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Design, synthesis and biological evaluation of bisnoralcohol derivatives as novel IRF4 inhibitors for the treatment of multiple myeloma
Jing-Zan Zhang, Lin Zhang, Xin Ding, et al.
European Journal of Medicinal Chemistry (2025) Vol. 285, pp. 117240-117240
Closed Access
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma
Sundar Jagannath, Carolyn C. Jackson, Jordan M. Schecter, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 5, pp. 339-350
Open Access | Times Cited: 4
Current Novel Targeted Therapeutic Strategies in Multiple Myeloma
Cindy Hsin-Ti Lin, Muhammad Junaid Tariq, Fauzia Ullah, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6192-6192
Open Access | Times Cited: 4
Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis
Shinsuke Iida, Yasuhiro Yasutomi, Yevgeniy Samyshkin, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0315932-e0315932
Open Access
Treatment landscape and disease burden of patients with multiple myeloma in Japan: a real-world survey
Yasuhiro Yasutomi, Amanda Ribbands, Emily Luke, et al.
Future Oncology (2025), pp. 1-10
Open Access
Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles
Carrie Bellerive, Mary Steinbach, Ann McNeill, et al.
Clinical journal of oncology nursing (2025) Vol. 29, Iss. 1, pp. E7–E16-E7–E16
Closed Access
Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma
K. Connolly, Daniel Brungs, E. Szeto, et al.
Current Oncology (2013) Vol. 21, Iss. 1, pp. 151-151
Open Access | Times Cited: 41
An Assessment of the Effectiveness and Safety of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma Patients with Relapsed or Refractory Disease: A Systematic Review and Meta-Analysis
Rita Pereira, Rui Bergantim
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4996-4996
Open Access | Times Cited: 3
Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma
Danai Dima, Razan Mansour, James A. Davis, et al.
European Journal Of Haematology (2024) Vol. 112, Iss. 6, pp. 975-983
Closed Access | Times Cited: 2
Multiple myeloma: clinical characteristics, current therapies and emerging innovative treatments targeting ribosome biogenesis dynamics
Mohamed Halaby Elbahoty, Bhavyasree Papineni, Rajeev S. Samant
Clinical & Experimental Metastasis (2024) Vol. 41, Iss. 6, pp. 829-842
Open Access | Times Cited: 2
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients
Mohamed Badawi, Benjamin Engelhardt, Edyta Dobkowska, et al.
Investigational New Drugs (2024)
Open Access | Times Cited: 1
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis)
María‐Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
Leukemia (2024)
Open Access
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma
Rie Nakamoto-Matsubara, Valentina Nardi, Nora Horick, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access
Ocular toxicities of FDA-approved antibody drug conjugates
Shaurey Vetsa, Stephanie Zhang, Walker Kay, et al.
Cutaneous and Ocular Toxicology (2024), pp. 1-12
Closed Access
The significance of progression-free survival as an endpoint in evaluating the therapeutic value of antineoplastic agents
J.A. Maroun
Current Oncology (2011) Vol. 18, Iss. S2
Open Access | Times Cited: 1
Real-world assessment of treatment multiple myeloma patients on the example of one hematology center
А. С. Лучинин, Н. В. Минаева
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice (2023), Iss. 3, pp. 29-37
Open Access
Page 1

Scroll to top